How to Order Wegovy (Semaglutide 2.4 mg)
Order Wegovy as a once-weekly subcutaneous injection starting at 0.25 mg with monthly dose escalation over 16 weeks to reach the maintenance dose of 2.4 mg, combined with lifestyle modifications including a reduced-calorie diet and increased physical activity. 1
Patient Eligibility Criteria
Before ordering, confirm your patient meets FDA-approved indications 1:
- BMI ≥30 kg/m² (obesity), OR
- BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
- Failed lifestyle interventions (diet and exercise alone)
Contraindications to Screen For
Do not prescribe Wegovy if the patient has 1:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or breastfeeding
- History of pancreatitis (use with caution)
Dosing Schedule
Follow this mandatory dose escalation schedule 2, 1:
| Weeks | Dose (subcutaneous, once weekly) |
|---|---|
| 1-4 | 0.25 mg |
| 5-8 | 0.5 mg |
| 9-12 | 1.0 mg |
| 13-16 | 1.7 mg |
| 17+ | 2.4 mg (maintenance) |
Critical implementation points:
- Gradual titration minimizes gastrointestinal adverse effects (nausea, vomiting, diarrhea) 2
- If patient cannot tolerate a dose, delay escalation by 4 weeks 1
- Inject subcutaneously in abdomen, thigh, or upper arm—same day each week, any time of day 1
- Some patients may achieve adequate response at 1.7 mg and can remain on this submaximal dose long-term 2
Prior Authorization Requirements
Prepare documentation for insurance approval:
- Document BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity
- Document failed lifestyle interventions (diet, exercise, behavioral modification for at least 3-6 months)
- List weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
- Note contraindications have been ruled out
The 2022 AGA guidelines strongly recommend adding pharmacological agents to lifestyle interventions in adults with obesity who have had inadequate response to lifestyle modifications alone, with semaglutide 2.4 mg conditionally recommended as the preferred agent given its magnitude of benefit 2.
Monitoring Schedule
Establish this follow-up protocol 3, 4:
- Months 1-3: Monthly visits to assess efficacy, tolerability, and adverse effects
- After 3 months: Every 3 months minimum
- Efficacy threshold at 16 weeks: If patient has not lost at least 4-5% body weight, consider discontinuing 5
- For patients with type 2 diabetes: Monitor blood glucose before starting and during treatment; may need to reduce insulin or sulfonylurea doses to prevent hypoglycemia 2
Patient Counseling Points
Educate patients on:
- Expected weight loss: 12-15% total body weight loss at 68 weeks (versus 2-3% with placebo) 6, 7
- Common side effects: Nausea (most common), vomiting, diarrhea, constipation—typically transient and mild-to-moderate 2, 5
- Thyroid tumor warning: Report any neck mass, difficulty swallowing, persistent hoarseness 1
- Pancreatitis risk: Report severe abdominal pain 2
- Gallbladder disease risk: Monitor for symptoms 2
- Lifelong therapy: Weight regain occurs after discontinuation; this is chronic disease management 8, 7
- Injection technique: Provide training on proper subcutaneous injection 1
Drug Interactions and Special Populations
Key considerations:
- Do not combine with other GLP-1 receptor agonists or DPP-4 inhibitors 2
- Delays gastric emptying: May affect absorption of oral medications requiring rapid onset 2
- No renal dose adjustment needed: Safe in all stages of kidney disease including ESRD 9, 1
- No hepatic dose adjustment needed 1
- Cardiovascular disease: Semaglutide reduces major adverse cardiovascular events in adults with established CVD 1
Prescription Details
Write the prescription as:
- Wegovy (semaglutide) 0.25 mg/0.5 mL subcutaneous injection
- Dispense: 4 single-dose pens (for weeks 1-4)
- Sig: Inject 0.25 mg subcutaneously once weekly on the same day each week
- Refills: Provide escalation schedule for subsequent doses (0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg)
The AGA 2022 guidelines give semaglutide 2.4 mg conditional recommendation with moderate-quality evidence, noting it may be prioritized over other approved anti-obesity medications for long-term treatment given its magnitude of net benefit 2. This represents the most recent high-quality guideline evidence supporting Wegovy as first-line pharmacotherapy for obesity management.